


## Catharanthine

<b>Cat. No.:</b>	HY-N0252		
<b>CAS No.:</b>	2468-21-5		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	336.43		
<b>Target:</b>	Calcium Channel		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (297.24 mM)  
 H<sub>2</sub>O : ≥ mg/mL  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		2.9724 mL	14.8619 mL	29.7239 mL
	5 mM		0.5945 mL	2.9724 mL	5.9448 mL
	10 mM		0.2972 mL	1.4862 mL	2.9724 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 3.5 mg/mL (10.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 3.5 mg/mL (10.40 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca<sup>2+</sup> channel (VOCC). Catharanthine has IC<sub>50</sub>s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

L-type calcium channel

#### In Vivo

Catharanthine ((+)-3,4-Didehydrocoronaridine; 0.5-20 mg/kg; IV; single dose) evokes dose-dependent reductions in both BP

---

and HR<sup>[1]</sup>.

Catharanthine (40 mg/kg; ip; single dose) with acute administration induces similar antidepressant-like activity in male and female mice at 1 h and 24 h<sup>[1]</sup>.

Catharanthine (20 mg/kg; ip; for 14 consecutive days) increases swimming time and decreases immobility time at D7 or D14 in mice<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

Animal Model:	13-week-old male SpragueDawley rats (300-350 g) <sup>[1]</sup>
Dosage:	0.5-20 mg/kg
Administration:	IV; single dose
Result:	Evoked rapid, transient reductions in BP and HR (lasting ,2 minutes) at low doses (0.5–5 mg/kg), whereas at higher doses (10 and 20 mg/kg), the BP and HR reductions were sustained.

---

## REFERENCES

[1]. Hugo R Arias, et al. (+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission. *Eur J Pharmacol.* 2023 Jan 15;939:175454.

[2]. Jadhav A, et al. Catharanthine dilates small mesenteric arteries and decreases heart rate and cardiac contractility by inhibition of voltage-operated calcium channels on vascular smooth muscle cells and cardiomyocytes. *J Pharmacol Exp Ther.* 2013 Jun;345(3):383-92.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA